NEW White Paper
Beyond the Barrier: Precision Preclinical Strategies for Targeting Glioblastoma
This white paper explores how integrated preclinical platforms—including orthotopic PDX models, humanized systems, and AI-driven predictive analytics—can bridge the gap between preclinical research and clinical success.
You Will Learn How To
- Select the right preclinical model: Compare cell lines, patient-derived cultures, PDX, and orthotopic systems for greater clinical relevance.
- Evaluate humanized and immunotherapy-ready systems: Examine GBM immune evasion and assess CAR-T and checkpoint inhibitor responses.
- Apply AI-driven predictive insights: Use CertisAI to forecast drug responses, identify synergistic combinations, and assess BBB penetration.
- Bridge the translational gap: Integrate multimodal endpoints, imaging, and molecular profiling to improve preclinical predictability.
Download White Paper
Proven in Preclinical GBM Research
Our collection of 57 low-passage brain cancer models—including 51 GBM specimens—represents the most comprehensive bank of clinically relevant models available to researchers today.
Your Translational Partner
Certis Oncology Solutions is an AI-enabled translational science company dedicated to realizing the promise of precision oncology. At the core of the company’s platform is CertisAI™, a patented machine-learning system designed to model the relationships between drug chemistry and tumor biology.
By integrating computational modeling with functional testing in clinically relevant patient-derived tumor models, Certis generates Oncology Intelligence®—highly predictive therapeutic response data that helps pharmaceutical companies select better drug candidates, design smarter development strategies, and improve the probability of clinical success.